RE: Wild volatility7 Aug 2025 12:56
Good afternoon all,
I have been revising some past info and have tried to establish some sort of predictive overview of what could be - rather than be totally optimistic and hit the high notes - i will give a middle of the road view which details what could be - as follows:
NHS / USA / others - adopts EpiSwitch® for 1 million tests/year - this I think is a very conservative estimate should they go ahead with tests.
Price per test: circa £100 this is a guestimate that i think is reasonable.
Revenue: £100 million/year
Net margin: 20% → £20 million profit - again rather lower than market norms.
Market cap could rise to ~£200–300 million (10–15x earnings)
With ~180 million shares outstanding, that implies:
Potential share price: £1.10–£1.65
£1000.00 of shares purchased at 0.005 ( some of us purchased lower ) = 200,000 shares X £1.10 / share = £219,000.00 profit - less the RR tax deductions :)
That's why I'm looking forward to news arriving - which now should be along shortly.
GLA.